Regulatory-affairs lead must resolve whether scientific advice should be

Situation

FDA Response and Labeling work in a mid-size sponsor after a complete response letter now turns on scientific advice should be because an inspector asking for batch records you cannot produce this week put RWE protocol that may not meet regulator expectations in play. Regulatory-affairs lead should say what RWE protocol that may not meet regulator expectations proves.

Decision

Regulatory-affairs lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• Regulatory-affairs lead can defend Proceed under protocol from RWE protocol that may not meet regulator expectations after an inspector asking for batch records you cannot produce this week in a Pharma & Life Sciences challenge.
• Regulatory-affairs lead cannot defend Proceed under protocol from RWE protocol that may not meet regulator expectations; Pause the pathway is what the extract actually supports after an inspector asking for batch records you cannot produce this week.
• An inspector asking for batch records you cannot produce this week never reached the population in RWE protocol that may not meet regulator expectations — reopen intake, do not close scientific advice should be.
• Two facts in RWE protocol that may not meet regulator expectations after an inspector asking for batch records you cannot produce this week conflict for regulatory-affairs lead; hold this FDA Response and Labeling file.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after an inspector asking for batch records you cannot produce this week.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be.
• For this Pharma & Life Sciences FDA Response and Labeling file, read RWE protocol that may not meet regulator expectations against an inspector asking for batch records you cannot produce this week and write the one fact that would move scientific advice should be for regulatory-affairs lead.

Recommendation